Orange Book product · Brand (NDA)
MYCIFRADIN
NEOMYCIN SULFATE
At a glance
Approved Prior to Jan 1, 1982
Approved
Brand (NDA)
Application
Not listed
TE code
None
Listed patents
Key dates
No patent or exclusivity dates are listed for this product.
Pharmaceutical detail
Active ingredient
NEOMYCIN SULFATE
Strength
EQ 87.5MG BASE/5ML
Dosage form
SOLUTION
Route
ORAL
TE code
Not listed
Application
NDA 050285
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a brand (NDA) product. Other products sharing this active ingredient are listed below.
- 2016NEOMYCIN SULFATEGeneric (ANDA)
ANDA 204435 · CHARTWELL MOLECULAR
- 2010NEOMYCIN SULFATEGeneric (ANDA)
ANDA 065468 · PHARMOBEDIENT
- 2006NEOMYCIN SULFATEGeneric (ANDA)
ANDA 065220 · SOLARIS PHARMA CORP
- 2002NEO-FRADINGeneric (ANDA)
ANDA 065010 · X GEN PHARMS
- —MYCIFRADINGeneric (ANDA)
ANDA 060520 · PHARMACIA AND UPJOHN
- —NEOBIOTICGeneric (ANDA)
ANDA 060475 · PFIZER
- —NEOMYCIN SULFATEGeneric (ANDA)
ANDA 060365 · BRISTOL MYERS SQUIBB
- —NEOMYCIN SULFATEGeneric (ANDA)
ANDA 060607 · LANNETT
- —NEOMYCIN SULFATEGeneric (ANDA)
ANDA 060385 · LILLY
- —NEOMYCIN SULFATEGeneric (ANDA)
ANDA 062173 · ROXANE
- —NEOMYCIN SULFATEGeneric (ANDA)
ANDA 061586 · SANDOZ
- —NEOMYCIN SULFATEGeneric (ANDA)
ANDA 060304 · TEVA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
